<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="uncharted territory as it fully succumbs to a novel coronavirus" exact="disease" post="(COVID-19) after it was initially reported in Wuhan, China"/>
 <result pre="China in late December 2019. COVID-19 is caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), one of the most"/>
 <result pre="in late December 2019. COVID-19 is caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), one of the most contagious"/>
 <result pre="late December 2019. COVID-19 is caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), one of the most contagious and"/>
 <result pre="Although coronaviruses were responsible for the previous epidemics such as" exact="Severe" post="Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome"/>
 <result pre="coronaviruses were responsible for the previous epidemics such as Severe" exact="Acute" post="Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS),"/>
 <result pre="were responsible for the previous epidemics such as Severe Acute" exact="Respiratory" post="Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), COVID-19"/>
 <result pre="responsible for the previous epidemics such as Severe Acute Respiratory" exact="Syndrome" post="(SARS) and Middle East Respiratory Syndrome (MERS), COVID-19 is"/>
 <result pre="such as Severe Acute Respiratory Syndrome (SARS) and Middle East" exact="Respiratory" post="Syndrome (MERS), COVID-19 is the first one to spread"/>
 <result pre="as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory" exact="Syndrome" post="(MERS), COVID-19 is the first one to spread to"/>
 <result pre="health measures â€&quot; including the enforcement of social distancing and" exact="total" post="lockdowns, aiming to limit the transmission of the disease."/>
 <result pre="symptoms, such as headache, fever and persistent dry cough, and" exact="atypical pneumonia" post="that can lead to life-threatening acute respiratory distress.2 While"/>
 <result pre="such as headache, fever and persistent dry cough, and atypical" exact="pneumonia" post="that can lead to life-threatening acute respiratory distress.2 While"/>
 <result pre="dry cough, and atypical pneumonia that can lead to life-threatening" exact="acute" post="respiratory distress.2 While most patients with COVID-19 present with"/>
 <result pre="cough, and atypical pneumonia that can lead to life-threatening acute" exact="respiratory" post="distress.2 While most patients with COVID-19 present with mild"/>
 <result pre="While most patients with COVID-19 present with mild symptoms, this" exact="disease" post="can cause hospitalisation, intensive care unit admission and death,"/>
 <result pre="those with comorbid conditions.3 The case fatality rate of the" exact="disease" post="is currently estimated at 2.7% and could be as"/>
 <result pre="drugs with good safety profiles and have activity against HIV," exact="hepatitis C" post="or similar virus strains might be the most feasible"/>
 <result pre="things: kill the virus or limit the severity of the" exact="disease" post="to increase chances of survival. Their antiviral activities are"/>
 <result pre="with potential activity against SARS-CoV-2a Lopinavir/ritonavir (LPV/r)Approved drug combination for" exact="HIV infection" post="A fixed dose combination medication indicated for the treatment"/>
 <result pre="potential activity against SARS-CoV-2a Lopinavir/ritonavir (LPV/r)Approved drug combination for HIV" exact="infection" post="A fixed dose combination medication indicated for the treatment"/>
 <result pre="dose combination medication indicated for the treatment and prevention of" exact="HIV/AIDS" post="(HIV-1 Protease inhibitor) â€¢In vitro and animal studies demonstrated"/>
 <result pre="outcomes (full recovery and discharge, progression from critical/severe to non-severe" exact="disease" post="status, PCR positive to negative, and/or maintenance of non-severe"/>
 <result pre="maintenance of non-severe status).11 â€¢A retrospective study investigated duration of" exact="viral" post="shedding in hospitalised COVID-19 patients (nÂ =Â 298) in"/>
 <result pre="2020 and 9 March 2020, reporting that median duration of" exact="viral" post="shedding was shorter in the LPV/r treatment group (nÂ"/>
 <result pre="(â‰¤10 days from symptom onset) could shorten the duration of" exact="viral" post="shedding.12 â€¢A study conducted on hospitalised COVID-19 patients (nÂ"/>
 <result pre="February 11, 2020 reported that there was no difference in" exact="viral" post="clearance time between patients who received antiviral therapy (LPVr"/>
 <result pre="â€¢A randomized, open-label trial comparing LPV/r vs standard care in" exact="adult" post="patients (nÂ =Â 199) hospitalised with severe COVID-19 demonstrated"/>
 <result pre="not significantly accelerate clinical improvement, reduce mortality, or diminish throat" exact="viral" post="RNA detectability.14 â€¢A retrospective cohort study in adults (nÂ"/>
 <result pre="including umifenovir might delay the progression of lung lesions and" exact="lower" post="the possibility of respiratory and gastrointestinal transmission.15 Although data"/>
 <result pre="the progression of lung lesions and lower the possibility of" exact="respiratory" post="and gastrointestinal transmission.15 Although data on the use of"/>
 <result pre="drugs metabolised by CYP3A and CYP2C19 RemdesivirExperimental drug for Ebola" exact="virus infection" post="A broad-spectrum antiviral agent (investigational nucleoside analogue that may"/>
 <result pre="metabolised by CYP3A and CYP2C19 RemdesivirExperimental drug for Ebola virus" exact="infection" post="A broad-spectrum antiviral agent (investigational nucleoside analogue that may"/>
 <result pre="A broad-spectrum antiviral agent (investigational nucleoside analogue that may block" exact="viral" post="nucleotide synthesis to stop viral replication) â€¢In-vitro studies reported"/>
 <result pre="nucleoside analogue that may block viral nucleotide synthesis to stop" exact="viral" post="replication) â€¢In-vitro studies reported that remdesivir inhibits SARS-CoV-2 replication"/>
 <result pre="safety and efficacy are being conducted. Camostat mesilate/nafamostat mesilateTreatment for" exact="pancreatitis" post="Serine protease/TMPRSS2 inhibitor â€¢In mice, camostat mesilate dosed at"/>
 <result pre="the clinically achievable concentration in humans reduced mortality following SARS-CoV" exact="infection" post="from 100% to 30â€&quot;35%. â€¢In vitro studies demonstrated that"/>
 <result pre="placebo-controlled trial exploring the impact of camostat mesilate on COVID-19" exact="Infection" post="has begun recruiting patients (nÂ =Â 180) to provide"/>
 <result pre="COVID-19 patients. Favipiravir (favilavir)Approved drug for novel influenza Inhibitor of" exact="viral" post="RNA-dependent RNA polymerase, causing chain termination and preventing RNA"/>
 <result pre="showed significantly better treatment effects of FPV in terms of" exact="disease" post="progression and viral clearance.23 â€¢A randomized open-label multicentre trial"/>
 <result pre="treatment effects of FPV in terms of disease progression and" exact="viral" post="clearance.23 â€¢A randomized open-label multicentre trial involving adult patients"/>
 <result pre="progression and viral clearance.23 â€¢A randomized open-label multicentre trial involving" exact="adult" post="patients with COVID-19 (nÂ =Â 240) aimed at exploring"/>
 <result pre="27 and some immunomodulatory and anti-inflammatory effects. It may prevent" exact="bacterial" post="superinfection. â€¢It has been used as adjunct therapy in"/>
 <result pre="has been used as adjunct therapy in the treatment of" exact="viral" post="respiratory tract infections such as influenza,28,29 albeit with contradictory"/>
 <result pre="been used as adjunct therapy in the treatment of viral" exact="respiratory" post="tract infections such as influenza,28,29 albeit with contradictory evidence.30"/>
 <result pre="as adjunct therapy in the treatment of viral respiratory tract" exact="infections" post="such as influenza,28,29 albeit with contradictory evidence.30 â€¢A retrospective,"/>
 <result pre="SARS-CoV-233, 34, 35 and reported to have immunomodulatory activity.32 â€¢Currently," exact="limited" post="data and clinical experience is available to substantiate the"/>
 <result pre="the pharmacokinetics and toxicity profile of chloroquine is well-established in" exact="malaria" post="treatment (the use of high dose for short period"/>
 <result pre="well-established in malaria treatment (the use of high dose for" exact="short" post="period or low dose for longer duration),32 additional data"/>
 <result pre="retinal damage (long term use); caution in patients with glucose-6-phosphate-dehdrogenase" exact="deficiency" post="and diabetic patients. Chloroquine may increase ciclosporin's concentration and"/>
 <result pre="has similar antiviral mechanism as chloroquine.37This may include inhibition of" exact="viral" post="enzymes or processes and ACE2 cellular receptor inhibition. â€¢Hydroxychloroquine"/>
 <result pre="to ICU or death at day 7 after hospital admission.41" exact="Ocular" post="effects (retinopathy),Rarely, cardiac toxicity, severe hypoglycaemia, agranulocytosis, thrombocytopenia Have"/>
 <result pre="hospital admission.41 Ocular effects (retinopathy),Rarely, cardiac toxicity, severe hypoglycaemia, agranulocytosis," exact="thrombocytopenia" post="Have relatively better drug interaction profile compared with chloroquine,"/>
 <result pre="day 6 than those who received hydroxychloroquine alone.36 â€¢A pilot" exact="uncontrolled" post="non-comparative observational study in Marseille, France investigated the efficacy"/>
 <result pre="ulceration or bleeding; salt and fluid retention, hypertensionRenal impairment, hyperkalaemia," exact="heart" post="failure NSAIDs may reduce antihypertensive effect of ACEIs and"/>
 <result pre="is recommended for patients who are currently prescribed such agents.50,51" exact="Renal" post="impairment, hyperkalaemia, angioedema, hypotension, persistent cough Interacts with NSAIDs,"/>
 <result pre="of hyperkalaemia and renal impairment Nitric oxide (inhaled) A selective" exact="pulmonary" post="vasodilator with demonstrated benefit in the treatment of acute"/>
 <result pre="selective pulmonary vasodilator with demonstrated benefit in the treatment of" exact="acute" post="respiratory distress syndrome (ARDS), one of the serious complications"/>
 <result pre="pulmonary vasodilator with demonstrated benefit in the treatment of acute" exact="respiratory" post="distress syndrome (ARDS), one of the serious complications of"/>
 <result pre="with demonstrated benefit in the treatment of acute respiratory distress" exact="syndrome" post="(ARDS), one of the serious complications of COVID-19.52 â€¢There"/>
 <result pre="evidence to support its use clinically for COVID-19 Thrombocytopenia, hypokalaemia," exact="hyperbilirubinemia" post="Its effect could be increased by sildenafil, leading to"/>
 <result pre="decline in international supplies,59 posing risk of drug shortages. The" exact="African" post="nations will especially be affected if this trend continues"/>
 <result pre="Africa, where the region carries a high share of global" exact="malaria" post="burden (&amp;gt;90% of global cases and deaths).60 Also, reports"/>
 <result pre="challenge in tackling the pandemic. Moreover, medication misinformation in the" exact="absence of" post="scientific validation can potentially spread unnecessary fear and panic,"/>
 <result pre="stockpiling of hydroxychloroquine has also resulted in substantial shortages affecting" exact="arthritis" post="or lupus patientsâ€&quot; conditions for which it has been"/>
 <result pre="hydroxychloroquine has also resulted in substantial shortages affecting arthritis or" exact="lupus" post="patientsâ€&quot; conditions for which it has been proven effective.62"/>
 <result pre="information with utmost accuracy and clarity. Being located at the" exact="heart" post="of the community and easy accessibility, community pharmacies can"/>
 <result pre="that continue to serve the public despite the declaration of" exact="total" post="lockdowns in several countries. Community pharmacists are vital part"/>
 <result pre="of the pandemic, symptoms, mode of transmission, promoting prevention and" exact="infection" post="control procedures in line with the public health guidelines."/>
 <result pre="and concerns about the potential shortage of hydroxychloroquine. Given the" exact="limited" post="evidence on efficacy and safety of hydroxychloroquine, the Therapeutic"/>
 <result pre="Further to this, TGA has released a statement highlighting the" exact="absence of" post="approved medicines for COVID-19 treatment, therefore prescribing of any"/>
 <result pre="channels within each country. â€¢Participate actively in COVID-19 hygiene and" exact="infection" post="control initiatives or strategies. â€¢Conduct health-education campaigns that promote"/>
 <result pre="registration with official NRAs, this is particularly important in resource" exact="limited" post="communities, in the shadow of a global crisis. â€¢Community"/>
 <result pre="humans in live animal markets or animal product markets including" exact="consumption" post="of raw meat, milk or animal organs. Conclusion Pharmacists"/>
 <result pre="interest. References References 1JiangF.DengL.ZhangL.CaiY.CheungC.W.XiaZ.Review of the clinical characteristics of coronavirus" exact="disease" post="2019 (COVID-19)J Gen Intern Med20201531625040 2CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features, evaluation and"/>
 <result pre="treatment coronavirus (COVID-19)StatPearls2020StatPearls Publishing[Internet] 3COVIDC.Severe outcomes among patients with coronavirus" exact="disease" post="2019 (COVID-19)â€&quot;United States, february 12â€&quot;march 16, 2020MMWR Morb Mortal"/>
 <result pre="Mortal Wkly Rep69122020 2734334632214079 4VerityR.OkellL.C.DorigattiI.Estimates of the severity of coronavirus" exact="disease" post="2019: a model-based analysisLancet Infect Dis2020 5LiG.De ClercqE.Therapeutic options"/>
 <result pre="2019 novel coronavirus (2019-nCoV)Nat Rev Drug Discov1932020 Mar14915032127666 6DongN.YangX.YeL.Genomic and" exact="Protein" post="Structure Modelling Analysis Depicts the Origin and Infectivity of"/>
 <result pre="and Infectivity of 2019-nCoV, a New Coronavirus Which Caused a" exact="Pneumonia" post="Outbreak in Wuhan, China2020BioRxiv 7HoffmannM.Kleine-WeberH.SchroederS.SARS-CoV-2 cell entry depends on"/>
 <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019â€�nCoVChembiochem2020 9YaoT.T.QianJ.D.ZhuW.Y.WangY.WangG.Q.A systematic review of"/>
 <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019â€�nCoVChembiochem2020 9YaoT.T.QianJ.D.ZhuW.Y.WangY.WangG.Q.A systematic review of lopinavir"/>
 <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019â€�nCoVChembiochem2020 9YaoT.T.QianJ.D.ZhuW.Y.WangY.WangG.Q.A systematic review of lopinavir therapy"/>
 <result pre="treatment optionJ Med Virol202010.1002/jmv.25729 10MartinezM.A.Compounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirusAntimicrob Agents Chemother6452020 Apr 21e00399-20 11HuL.ChenS.FuY.Risk factors associated"/>
 <result pre="323 COVID-19 patients in wuhan, ChinaMedrxiv202010.1101/2020.03.25.20037721 12YanD.LiuX-yZhuY-nFactors associated with prolonged" exact="viral" post="shedding and impact of Lopinavir/Ritonavir treatment in patients with"/>
 <result pre="treatment in patients with SARS-CoV-2 infectionMedrxiv202010.1101/2020.03.22.20040832 13CaiQ.HuangD.OuP.COVIDâ€�19 in a designated" exact="infectious diseases" post="hospital outside hubei province, ChinaAllergy2020 Apr 210.1111/all.14309 14CaoB.WangY.WenD.A trial"/>
 <result pre="18NEJMoa2001282 15DengL.LiC.ZengQ.Arbidol combined with LPV/r versus LPV/r alone against Corona" exact="Virus Disease" post="2019: a retrospective cohort studyJ Infect2020 Mar 11S0163-4453(20)30113-4 16LiuF.XuA.ZhangY.Patients"/>
 <result pre="15DengL.LiC.ZengQ.Arbidol combined with LPV/r versus LPV/r alone against Corona Virus" exact="Disease" post="2019: a retrospective cohort studyJ Infect2020 Mar 11S0163-4453(20)30113-4 16LiuF.XuA.ZhangY.Patients"/>
 <result pre="Mar 314881494 18ZhouF.YuT.DuR.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe" exact="acute" post="respiratory syndrome coronavirus 2 with high potencyJ Biol Chem202010.1074/jbc.RA120.013679RA120.013679"/>
 <result pre="direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute" exact="respiratory" post="syndrome coronavirus 2 with high potencyJ Biol Chem202010.1074/jbc.RA120.013679RA120.013679 21GreinJ.OhmagariN.ShinD.Compassionate"/>
 <result pre="antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory" exact="syndrome" post="coronavirus 2 with high potencyJ Biol Chem202010.1074/jbc.RA120.013679RA120.013679 21GreinJ.OhmagariN.ShinD.Compassionate use"/>
 <result pre="antiviral activity of remdesivir (GS-5734) in participants with moderate coronavirus" exact="disease" post="(COVID-19) compared to standard of care treatmentClinicalTrials.gov Identifier: NCT042927302020Accessed"/>
 <result pre="25TranD.H.SugamataR.HiroseT.Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A (H1N1) pdm09" exact="virus infection" post="by interfering with virus internalization processJ Antibiot (Tokyo)72102019 Oct75976831300721"/>
 <result pre="a 15-membered macrolide antibiotic, inhibits influenza A (H1N1) pdm09 virus" exact="infection" post="by interfering with virus internalization processJ Antibiot (Tokyo)72102019 Oct75976831300721"/>
 <result pre="Oct75976831300721 26RetallackH.Di LulloE.AriasC.Zika virus cell tropism in the developing human" exact="brain" post="and inhibition by azithromycinProc Natl Acad Sci U S"/>
 <result pre="Sci U S A113502016 Dec 13144081441327911847 27LiC.ZuS.DengY.-Q.Azithromycin protects against zika" exact="virus infection" post="by upregulating virus-induced type I and III interferon responsesAntimicrob"/>
 <result pre="U S A113502016 Dec 13144081441327911847 27LiC.ZuS.DengY.-Q.Azithromycin protects against zika virus" exact="infection" post="by upregulating virus-induced type I and III interferon responsesAntimicrob"/>
 <result pre="13144081441327911847 27LiC.ZuS.DengY.-Q.Azithromycin protects against zika virus infection by upregulating virus-induced" exact="type I" post="and III interferon responsesAntimicrob Agents Chemother63122019 Sep 16e00394-19 28LeeN.WongC.-K.ChanM.C.Anti-inflammatory"/>
 <result pre="efficacy of oseltamivir-azithromycin combination therapy in prevention of influenza-a (H1N1)" exact="infection" post="complications and rapidity of symptom reliefExpert Rev Respir Med1452020"/>
 <result pre="Med1452020 May53354132053044 30ArabiY.M.DeebA.M.Al-HameedF.Macrolides in critically ill patients with Middle East" exact="Respiratory" post="SyndromeInt J Infect Dis812019 Apr18419030690213 31WangD.HuB.HuC.Clinical characteristics of 138"/>
 <result pre="31WangD.HuB.HuC.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâ€&quot;infected" exact="pneumonia" post="in Wuhan, ChinaJ Am Med Assoc2020 Feb 7e201585 32DevauxC.A.RolainJ.-M.ColsonP.RaoultD.New"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 9ciaa237"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 9ciaa237 35WangM.CaoR.ZhangL.Remdesivir"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis2020 Mar 9ciaa237 35WangM.CaoR.ZhangL.Remdesivir and"/>
 <result pre="chloroquine and its hydroxyl analogue to face bacterial, fungal and" exact="viral" post="infections in the 21st centuryInt J Antimicrob Agents3042007 Oct29730817629679"/>
 <result pre="and its hydroxyl analogue to face bacterial, fungal and viral" exact="infections" post="in the 21st centuryInt J Antimicrob Agents3042007 Oct29730817629679 38CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.A"/>
 <result pre="of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19" exact="infection" post="with oxygen requirement: results of a study using routinely"/>
 <result pre="hydroxychloroquineRes Soc Adm Pharm2020 Apr 19S1551-7411(20)30391-0 45collab: US Centers for" exact="Disease" post="Control and PreventionCoronavirus disease 2019 (COVID-19): information for clinicians"/>
 <result pre="Apr 19S1551-7411(20)30391-0 45collab: US Centers for Disease Control and PreventionCoronavirus" exact="disease" post="2019 (COVID-19): information for clinicians on therapeutic options for"/>
 <result pre="clinicians on therapeutic options for COVID-19 patientshttps://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html2020 46FangL.KarakiulakisG.RothM.Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?Lancet"/>
 <result pre="therapeutic options for COVID-19 patientshttps://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html2020 46FangL.KarakiulakisG.RothM.Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection?Lancet Respir Med842020 Apre2132171062"/>
 <result pre="risk for COVID-19 infection?Lancet Respir Med842020 Apre2132171062 47ZhengY.-Y.MaY.-T.ZhangJ.-Y.XieX.COVID-19 and the" exact="cardiovascular" post="systemNat Rev Cardiol1752020 May25926032139904 48LuR.ZhaoX.LiJ.Genomic characterisation and epidemiology of"/>
 <result pre="49LiuY.YangY.ZhangC.Clinical and biochemical indexes from 2019-nCoV infected patients linked to" exact="viral" post="loads and lung injurySci China Life Sci6332020 Mar36437432048163 50American"/>
 <result pre="51European Society of CardiologyPosition statement of the ESC council on" exact="hypertension" post="on ACE-inhibitors and angiotensin receptor blockershttps://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang2020 52GebistorfF.KaramO.WetterslevJ.AfshariA.Inhaled nitric oxide"/>
 <result pre="on ACE-inhibitors and angiotensin receptor blockershttps://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang2020 52GebistorfF.KaramO.WetterslevJ.AfshariA.Inhaled nitric oxide for" exact="acute" post="respiratory distress syndrome (ARDS) in children and adultsCochrane Database"/>
 <result pre="ACE-inhibitors and angiotensin receptor blockershttps://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang2020 52GebistorfF.KaramO.WetterslevJ.AfshariA.Inhaled nitric oxide for acute" exact="respiratory" post="distress syndrome (ARDS) in children and adultsCochrane Database Syst"/>
 <result pre="angiotensin receptor blockershttps://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang2020 52GebistorfF.KaramO.WetterslevJ.AfshariA.Inhaled nitric oxide for acute respiratory distress" exact="syndrome" post="(ARDS) in children and adultsCochrane Database Syst Rev201662016 Jun"/>
 <result pre="Jun 27CD002787 53Ã…kerstrÃ¶mS.Mousavi-JaziM.KlingstrÃ¶mJ.LeijonM.Ã…LundkvistMirazimiA.Nitric oxide inhibits the replication cycle of severe" exact="acute" post="respiratory syndrome coronavirusJ Virol7932005 Feb1966196915650225 54BiospaceBiospace mallinckrodt evaluates the"/>
 <result pre="27CD002787 53Ã…kerstrÃ¶mS.Mousavi-JaziM.KlingstrÃ¶mJ.LeijonM.Ã…LundkvistMirazimiA.Nitric oxide inhibits the replication cycle of severe acute" exact="respiratory" post="syndrome coronavirusJ Virol7932005 Feb1966196915650225 54BiospaceBiospace mallinckrodt evaluates the potential"/>
 <result pre="53Ã…kerstrÃ¶mS.Mousavi-JaziM.KlingstrÃ¶mJ.LeijonM.Ã…LundkvistMirazimiA.Nitric oxide inhibits the replication cycle of severe acute respiratory" exact="syndrome" post="coronavirusJ Virol7932005 Feb1966196915650225 54BiospaceBiospace mallinckrodt evaluates the potential role"/>
 <result pre="and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus" exact="pneumonia" post="(COVID-19) patients who are still positive on virus detection"/>
 <result pre="during the covid-19 pandemicN Engl J Med2020 Apr 14 63WHOCoronavirus" exact="Disease" post="(COVID-19) Advice for the Public: Myth Busters2020World Health OrganisationAccessedhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters"/>
 <result pre="the Public: Myth Busters2020World Health OrganisationAccessedhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters 64Pharmaceutcal Society of AustraliaCoronavirus" exact="Disease" post="(COVID-19) Information for Pharmacists2020https://www.psa.org.au/coronavirus/#1584417715498-63dab0ae-a2bd 65collab: The Pharmacy Guild of"/>
</results>
